10th European AIDS Conference/EACS, Dublin, November 2005
1 Liver-related Deaths among HIV-infected Persons; Data from the D:A:D Study. R Weber, N Friis-Møller, CA Sabin, P Reiss, A D’Arminio Monforte, F Dabis, W El-Sadr, S De Wit, L Morfeldt, MG Law, C Pradier, G Calvo, O Kirk, AN Phillips, JD Lundgren on behalf of the D:A:D study group.
2 Comparison of resistance profiles between patients starting nevirapine and efavirenz in EuroSIDA. W Bannister, L Ruiz, B Ledergerber, A Cozzi-Lepri, O Kirk, S Staszewski,
C Loveday, B Clotet, A Phillips, J Lundgren for the EuroSIDA study group.
3 Evolution of drug resistance in HIV infected patients remaining on a virologically failing cART regimen. A Cozzi-Lepri, AN Phillips, L Ruiz, B Clotet, C Loveday, J Kjaer,
N Clumeck, L Viksna, F Antunes, L Machala and JD Lundgren.
4 Pilot of the CoDe (Coding of Death) project - a standardized approach to code causes of death in HIV infected individuals. CH Olsen, N Friis-Møller, A d'Arminio Monforte,
G Chene, R Davey, S De Wit, F De Wolf, M Egger, M Ellefson,W El-Sadr, O Kirk, M Law,
B Ledergerber, C Lewden, S Mateu, A Mocroft, T Peto, A Phillips, C Pradier, P Reiss,
F Rhame, C Sabin, J Sterne, R Weber, B Åkerlund, JD Lundgren, for the CoDe Working Group.
1 Use of antimycotic therapy is an independent risk factor for HIV-disease progression among patients with a CD4 count above 200/µL in the era of combination antiretroviral therapy . D Podlekareva, A Mocroft, P Reiss, P Aldins, C Katlama, B Ledergerber, HJ Stellbrink, AD Monforte, O Kirk, JD Lundgren
Abstract PS 2/1
2 Is there an association between the endpoints in trials of virological efficacy and clinical long-term prognosis? O Kirk, A Mocroft, P Reiss, B Ledergerber, B Knysz, G Fätkenheuer, S Chaplinskas, JM Gatell, A Phillips, JD Lundgren for the EuroSIDA Study Group
Abstract PS 3/4
3 Clinical progression according to HIV drug resistance accumulated on antiretroviral therapy in EuroSIDA. A Cozzi-Lepri, A Phillips, A Mocroft, O Kirk, L Ruiz and JD Lundgren.
Abstract PS 6/4
4 Is there evidence for an increase in the death rate from liver-related diseade in patients with HIV? The EuroSIDA study. JD Lundgren, A Mocroft, V Soriano, J ROchstroh, P Reiss, O Kirk, S de Wit, JM Gatell, B Clotet, A Phillips
Abstract PS 7/2
3rd IAS Conference on HIV Pathogensis and Treatment, Rio de Janeiro, July 2005
1 Rates of viral suppression and regimen change according to initial HAAR regimen. A collaborative analysis of 12 prospective cohort studies. R Hogg, J Lundgren, D Costagliola, A d´Arminio Monforte, B Ledergerber, F de Wolf, G Fusco, S Staszewski, G Chene, A Phillips, J Gil, N Schmeisser, M May, J Sterne, M Egger.
2 Impact of Lamivudine (3TC) on the risk of liver related death (LRD) in 2,041 HBsAg and HIV-positive inidividuals. Results of an intercohort analysis. M Puoti, A Cozzi-Lepri, G Parainfo, J Lundgren, M Rickenback, I Suarez-Lozano, M Winnock, A Gervais, J Gill, J Rockstroh, C Mussini, A Castagna, A De Luca, A d´Arminio Monforte.
3 Risk factors for new onset diabetes mellitus (DM) in HIV patients. C Sabin, N Friis-Møller, P Reiss, R Weber, A d´Arminio Monforte, F Dabis, W El-Sadr, S de Wit, S Mateu, O Kirk, C Pradier, L Morfeldt, M Law, J Lundgren.
3rd European Resistance Conference, Athens, March 2005
1 The COLATE trial: comparison of the evolutionary distance for protease and reverse transcriptase sequences. J Kjær
Poster(352 KB) Abstract
2 How to read viral load in patients with virus variants that you can not suppress.
12th Conference on Retroviruses and Opportunistic Infections, Boston, February 2005
1 Cardiovascular outcomes in HIV infection. JD Lundgren et al
2 Changes over time in antiretroviral therapy (ART) use and risk factors for cardiovascular disease (CVD) in the D:A:D study. C Sabin, L Morfeldt, N Friis-Møller, M Rickenbach, P Reiss, A D´Arminio Monforte, C Pradier, O Kirk, G Calvo, M Law, P Mercié,
W El-Sadr, S De Wit, JD Lundgren on behalf of the D:A:D study group.
Poster # 866(70 KB) Abstract
3 Relationship between prolonges exposure to combination antiretroviral therapy (cART) and myocardial infarction (MI): effect of sex, age and lipid changes. W El-Sadr, P Reiss, S De Wit, A D´Armino Monforte, R Thiebaut, L Morfeldt, R Weber, C Pradier, G Calvo, MG Law, O Kirk, C Sabin, N Friis-Møller JD Lundgren on behalf of the D:A:D study group.
4 HIV and Non-HIV-related deaths and their relationship to immunodeficiency; the D:A:D study. R Weber, N Friis-Møller, C Sabin, P Reiss, A D´Arminio Monforte, F Dabis, W El-Sadr, S De Wit, L Morfeldt, MG Law, C Pradier, G Calvo, C Holkmann Olsen, AN Phillips, JD Lundgren on behalf of the D:A:D study group.
Poster #595 (75 KB) Abstract
5 Risk of AIDS and death at given HIV-RNA and CD4 count level, according to specific antiretroviral drugs in the CART regimen. C Holkmann-Olsen1, J Gatell, B Ledergerber, C Katlama, N Friis-Møller, J Weber, A Horban, S Staszewski, J Lundgren, A Phillips, and EuroSIDA
Poster #601(78 KB) Abstract
6 HIV-1 subtypes and virological response to HAART in Europe. W Bannister, L Ruiz, C Loveday, S Vella, K Zilmer, D Podlekareva, B Knysz, A Phillips, J Lundgren, A Mocroft and the EuroSIDA study group
Poster #598(157 KB) Abstract
7 Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on virological response to therapy. A Cozzi-Lepri, L Ruiz, C Loveday, A Phillips, B Clotet, P Reiss, J Lundgren, and EuroSIDA Study Group
Poster #708(113 KB) Abstract
8 A Comparison of Risk of Treatment Limiting Adverse Events in HCV-co-infected vs Non-co-infected persons with HIV in EuroSIDA. JD Lundgren, J Rockstroh, V Soriano, B Ledergerber, O Kirk, E Vinogradova, P Reiss, C Katlama, A Blaxhult, A Mocroft, and EuroSIDA Study Group
Poster #946(137 KB) Abstract
9 Mortality Rates According to Initial HAART Regimen: A Collaborative Analysis of 12 Prospective Cohort Studies. R Hogg, J Lundgren, D Costagliola, A Monforte, B Ledergerber, F de Wolf, G Fusco, S Staszewski, G Chêne, A Phillips, J Gill, J Rockstroh, M May, J Sterne, M Egger, and ART Cohort Collaboration.
Updated: 06 Feb 2006